• Conditions & Treatments

  • Learn from the Experts

  • Support Your Practice

  • Conferences & Highlights

  • Community Resources

  • Our Expert Network

CME & EducationAbout Us
Loading...
CME & EducationAbout Us
Loading profile...
  • Conditions & Treatments

  • Learn from the Experts

  • Support Your Practice

  • Conferences & Highlights
  • Community Resources

  • Our Expert Network
  1. Home
  2. Videos
  3. Discourses In Dermatology
  4. Advances Acne Treatment 2024 Highlights What To Watch 2025

Advances in Acne Treatment: 2024 Highlights and What to Watch for in 2025

Featuring:
JBJohn Barbieri, MD, MBA, FAADFaculty
Updated:Jan 16, 2025
AcneAcne

About this video

In this episode of Topical Conversations, Dr John Barbieri of Brigham and Women’s Hospital in Boston provides an overview of the exciting developments in acne treatment in 2024 and shares key innovations to look forward to in 2025. 

2024: a year of breakthroughs in acne care 

Fixed-dose combination therapy 

One of the standout advancements of 2024 was the introduction of a fixed-dose combination therapy comprising clindamycin, adapalene, and benzoyl peroxide. Dr. Barbieri highlights this as the most efficacious single-agent topical treatment currently available for acne. 

  • Optimized vehicle: Unlike other products, this combination utilizes an advanced formulation to minimize irritation and improve patient comfort. 
  • Enhanced adherence and outcomes: Studies comparing fixed-dose combinations to separately used components have demonstrated improved adherence rates and superior clinical outcomes. 
  • Comprehensive mechanism of action: Pairing this fixed-dose therapy with another agent, such as clascoterone, addresses all major acne pathways, offering a robust, well-tolerated treatment option. 

1726 nm lasers: targeted sebaceous gland therapy 

Another significant development in 2024 is the emergence of 1726 nanometer lasers, including devices like AviClear and Accure. 

  • Precision treatment: These lasers directly target sebaceous glands, providing a focused alternative to systemic therapies like isotretinoin, which often carry off-target side effects such as eye dryness and systemic impacts. 
  • Clinical efficacy: Clinical trials show promising results: 
    • Around 40% of patients with moderate to severe acne achieve clear or almost clear skin for up to 6 months post-treatment. 
    • Eighty to 90% of patients experience at least a 50% reduction in inflammatory lesions. 
  • Well-tolerated option: While transient acne worsening can occur, the overall side effect profile is favorable, offering a new avenue for patients who cannot or prefer not to use systemic treatments. 

Looking ahead: innovations in 2025 and beyond 

Spongilla lacustris extract mask 

A topical treatment derived from Spongilla lacustris extract is under development as a once-weekly mask with dual anti-inflammatory and antimicrobial properties. 

  • Phase 2 success: Early trials have shown promise, paving the way for this novel therapy to become an accessible option for patients with acne 

N-acetyl-GED 

Another exciting candidate is a topical treatment targeting the sebaceous glands. 

  • Direct Action on Sebaceous Glands: This innovation offers a rare mechanism of action for topical therapies, focusing on reducing sebum production, oiliness, and acne-promoting factors like C. acnes bacteria 
  • Potential for Impact: With few existing treatments addressing sebaceous gland activity directly, this agent holds potential to reshape acne management 

The Road Ahead in Acne Treatment 

As we look ahead to 2025, the landscape of acne treatment is set to evolve with a mix of innovative therapies and technologies. Fixed-dose combination topicals, advanced laser technologies, and novel agents in development offer new options to address the complex mechanisms of acne. These advancements provide dermatologists with more tools to tailor treatments to individual patient needs. 

By staying informed and incorporating these developments into practice, dermatologists can continue to refine their approach to managing acne and improve overall outcomes.

1
Integrating 31-GEP Testing into SLNB Decision-Making in Cutaneous Melanoma
5:04

Integrating 31-GEP Testing into SLNB Decision-Making in Cutaneous Melanoma

2
What Changes When We Treat Psoriasis as Systemic Disease?
7:01

What Changes When We Treat Psoriasis as Systemic Disease?

3
Who to Look for and When to Act
2:31

Who to Look for and When to Act

4
How Oral TYK2 Inhibition Is Showing Up in Real Decisions
10:38

How Oral TYK2 Inhibition Is Showing Up in Real Decisions

5
Injecting on Bone: A Practical Approach to Filler Safety
0:44

Injecting on Bone: A Practical Approach to Filler Safety

6
Cosibelimab in Advanced Cutaneous Squamous Cell Carcinoma: ≥2-Year Follow-Up from the Pivotal Study
8:12

Cosibelimab in Advanced Cutaneous Squamous Cell Carcinoma: ≥2-Year Follow-Up from the Pivotal Study

7
Earlier Treatment, Different Outcomes: Secukinumab and the HS Disease Course
2:51

Earlier Treatment, Different Outcomes: Secukinumab and the HS Disease Course

8
Fast Relief, Sustained Control: What Remibrutinib Shows in CSU
2:42

Fast Relief, Sustained Control: What Remibrutinib Shows in CSU

9
Bullous Pemphigoid: The Evolving Treatment Landscape
8:22

Bullous Pemphigoid: The Evolving Treatment Landscape

10
Confirming BP Diagnosis and Choosing Treatment
7:42

Confirming BP Diagnosis and Choosing Treatment

11
How Dermatologists Use Hedgehog Inhibitors for Locally Advanced BCC
4:08

How Dermatologists Use Hedgehog Inhibitors for Locally Advanced BCC

12
What Four Years Can Tell Us About Treating Moderate to Severe HS
3:29

What Four Years Can Tell Us About Treating Moderate to Severe HS

13
Early Response, Sustained Control: 52-Week Outcomes With Remibrutinib
3:18

Early Response, Sustained Control: 52-Week Outcomes With Remibrutinib

14
A Review of Dermoscopy Techniques With Michelle Tarbox, MD
1:28

A Review of Dermoscopy Techniques With Michelle Tarbox, MD

15
Leading With Intention in Aesthetic Assessment
2:57

Leading With Intention in Aesthetic Assessment

16
Recognizing Bullous Pemphigoid Earlier in Clinical Practice
1:52

Recognizing Bullous Pemphigoid Earlier in Clinical Practice

17
Tildrakizumab in Psoriasis: Adherence, Persistence, and the Role of In-Office Administration
10:34

Tildrakizumab in Psoriasis: Adherence, Persistence, and the Role of In-Office Administration

18
Advancing Bullous Pemphigoid Care: Clinical Insights From Dr. Del Rosso
23:00

Advancing Bullous Pemphigoid Care: Clinical Insights From Dr. Del Rosso

19
Strengthening Confidence in Hedgehog Inhibitors for Locally Advanced Basal Cell Carcinoma
8:33

Strengthening Confidence in Hedgehog Inhibitors for Locally Advanced Basal Cell Carcinoma

20
Advancing Melanoma Prognostics: Clinical Evidence Supporting the 31-GEP Test
6:53

Advancing Melanoma Prognostics: Clinical Evidence Supporting the 31-GEP Test

21
Topical Truths: Managing AD in the Real World
21:54

Topical Truths: Managing AD in the Real World

22
The Oral Conversation: How We Talk to Patients About Systemic Therapy Today
30:51

The Oral Conversation: How We Talk to Patients About Systemic Therapy Today

23
Part 4: How Dermatologists Approach SI/B Warnings in Daily Practice
10:00

Part 4: How Dermatologists Approach SI/B Warnings in Daily Practice

24
Part 1: Psoriasis and Mental Health: Understanding Depression and Suicidality Risk
10:04

Part 1: Psoriasis and Mental Health: Understanding Depression and Suicidality Risk

25
Part 2: Psoriasis and Mental Health: The Inflammatory and Biochemical Pathways
9:36

Part 2: Psoriasis and Mental Health: The Inflammatory and Biochemical Pathways

26
Part 3: Psoriasis and Mental Health: How to Navigate SI/B Warnings With Patients
9:51

Part 3: Psoriasis and Mental Health: How to Navigate SI/B Warnings With Patients

27
Fall Clinical Continuity Experience - Vtama - Lecture Recap Video
0:35

Fall Clinical Continuity Experience - Vtama - Lecture Recap Video

28
Four Years of Data: Durability and Distinction with TYK2 Inhibition
3:09

Four Years of Data: Durability and Distinction with TYK2 Inhibition

29
What an Oral Option Means for Psoriasis Care
2:34

What an Oral Option Means for Psoriasis Care

30
LAUNCH ALERT: FDA Approves Anzupgo (Delgocitinib) Cream for Moderate-to-Severe Chronic Hand Eczema in Adults
8:39

LAUNCH ALERT: FDA Approves Anzupgo (Delgocitinib) Cream for Moderate-to-Severe Chronic Hand Eczema in Adults

31
Bimzelx in Focus: Versatile Care for Enhanced Dermatologic Outcomes
7:58

Bimzelx in Focus: Versatile Care for Enhanced Dermatologic Outcomes

32
Discover VTAMA: A Next-Generation Treatment for Plaque Psoriasis
4:59

Discover VTAMA: A Next-Generation Treatment for Plaque Psoriasis

33
VTAMA: A New Standard in Psoriasis Management
4:59

VTAMA: A New Standard in Psoriasis Management

34
Exploring the MyPath Melanoma Test for Guiding Management and Care Decisions in Patients with Ambiguous Lesions
18:17

Exploring the MyPath Melanoma Test for Guiding Management and Care Decisions in Patients with Ambiguous Lesions

35
Bimekizumab for Plaque Psoriasis: Its Impact in Clinical Practice
16:27

Bimekizumab for Plaque Psoriasis: Its Impact in Clinical Practice

36
Bimekizumab for Plaque Psoriasis: Insights into Efficacy, Safety, and Dosing
6:45

Bimekizumab for Plaque Psoriasis: Insights into Efficacy, Safety, and Dosing

37
Psoriasis mechanism of disease: Pathogenesis
8:27

Psoriasis mechanism of disease: Pathogenesis

38
Psoriasis mechanism of disease: Genetic, environmental, and lifestyle factors
12:45

Psoriasis mechanism of disease: Genetic, environmental, and lifestyle factors

Dermsquared

The leading solutions platform for dermatology professionals to elevate patient care.

Helpful Links

Terms of Service

Editorial & Medical Review Policy

Privacy Policy

Cookie Policy

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2026 dermsquared | All Rights Reserved

Continuing Education

0.75 Credits

DermInsider - VGR Session 11

Welcome to DermInsider - A Virtual Grand Rounds SeriesNew name, the same great CME!DermInsider consists of regularly scheduled CME sessions on a variety of dermatological diseases, delivered by the top experts in dermatology. Please join us for this week's session:Wednesday, October 15, 20258 PM ET / 5 PM PTThe Science of Botulinum Toxin Type A – Mark Nestor, MD, PhDClinical Updates in Acne and Rosacea – Linda Stein Gold, MD